IMRT is utilized for treatment in head and neck sites to maximize target coverage and decrease normal tissue toxicity, such as xerostomia and dysphagia. The most common at-risk nodal levels for head and neck cancers typically include levels I to VII and the lateral retropharyngeal lymph nodes (RPLN).
This is a preview of subscription content, log in to check access
Caudell JJ et al (2010) Comparison of methods to reduce dose to swallow-related structures in head and neck cancer. Int J Radiat Oncol Biol Phys 77(2):462–467CrossRefGoogle Scholar
Feng FY et al (2010) Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 28(16):2732–2738CrossRefGoogle Scholar
Hall WH et al (2008) Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 72(5):1362–1367CrossRefGoogle Scholar
Lee NY et al (2007) Choosing an intensity-modulated radiation therapy technique in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys 68(5):1299–1309CrossRefGoogle Scholar
Levendag PC et al (2007) Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 85(1):64–73CrossRefGoogle Scholar
O’Sullivan B et al (2001) The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 51(2):332–343CrossRefGoogle Scholar